Canada's Knight Therapeutics Q4 revenue beats estimates on acquisitions strength

Knight Therapeutics

19/03/2026 11:42

((This story was generated using AI and automation, please see
disclaimer https://bit.ly/rtrsnai))
    
    Overview
  
    * Canada specialty pharma firm's Q4 revenue rose 37% yr/yr, beating analyst expectations
    * Adjusted EBITDA and cash flow from operations reached record highs for the year
    * Growth driven by Paladin and Sumitomo acquisitions and key product expansion

    
    Outlook
  
    * Knight Therapeutics expects 2026 revenues between C$490 mln and C$510 mln
    * Company sees 2026 adjusted EBITDA at approximately 15% of revenues

    
    Result Drivers
  
    * ACQUISITIONS - Revenue growth was primarily driven by incremental contributions from the Paladin and Sumitomo transactions
    * KEY PROMOTED PRODUCTS - Growth of key promoted products contributed to higher revenue, especially in Oncology/Hematology and Neurology
    * PRODUCT LAUNCHES - New product launches and expanded portfolio, including innovative assets in Canada and Latin America, supported revenue growth

    
Company press release:  ID:nGNX6m1tmD 
    
    Key Details
  
                               
                               
 Metric    Beat/Mis  Actual    Consensu
           s                   s
                               Estimate
                               
                               
 Q4        Beat      C$133.11  C$117.35
 Revenue             mln       mln (4
                               Analysts
                               )
 Q4 Net              C$8.85     
 Income              mln       
 Q4                  C$58.51    
 Operatin            mln       
 g                             
 Expenses                      
    
    Analyst Coverage
  
    * The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
    * The average consensus recommendation for the pharmaceuticals peer group is "buy"
    * Wall Street's median 12-month price target for Knight Therapeutics Inc is C$7.73, about 25.2% above its March 18 closing price of C$6.17
    * The stock recently traded at 130 times the next 12-month earnings vs. a P/E of 255 three months ago

    
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)